STOCK ALERT RJV Networks, Inc. (OTC BB: RJNV) Press Release----Source: RJV Network, Inc. (OTC BB: RJVN) Announces Cancer Treatment Therapy Advances Using BioCurex RECAF Technology Through A Licensing Agreement with its BioKinetix (acquisition underway).
Thursday December 19, 10:00pm ET RJV Network, Inc. (OTC BB:RJVN.OB - News), a Nevada corporation, is in the process of acquiring BioKinetix Research Inc. BELLEVUE, Wash., and announces further developments of the combined Company revolutionary cancer treatment therapy, now just months away from formal market testing to begin. BioCurex Inc. (OTC BB:BOCX.OB - News) announced on December 16th that it has completed a licensing agreement with BioKinetix (being acquired by OTC BB: RJVN) to use BioCurex's RECAF technology. The license will allow BioKinetix to use its InNexus Super Antibody platform technology to create therapeutic antibodies; then combining RECAF antibodies with RJVN Super Antibody technology could give BioKinetix the potential to create both highly potent therapeutic antibodies, as well as vaccines to immunize against the RECAF receptor, creating a highly effective treatment for most cancers as agreed upon by many world renowned molecular biologists, including Dr. John Todd of RJVN BioKinetix. BioCurex, Inc. is a biotechnology company that is developing products based on patented / proprietary technology in the areas of cancer diagnosis, tumor imaging ad therapeutics. The technology identifies a cancer marker known as RECAF(tm), which is found on malignant cells from a variety of cancer types but absent in most normal or benign cells. Detailed information about BioCurex may be obtained from their website at biocurex.com . Created over ten years of expensive research and development, RECAF technology is able to effectively locate molecules (markers) that are present on active cancer cells, but not on healthy cells. The combination of these two technologies gives BioKinetix the potential to create a series of therapeutic products that may treat most cancers. The therapeutics to be developed are monoclonal antibodies that mark growth factor receptor on cancer tissue. Combining RECAF antibodies with Super Antibody technology will give BioKinetix the potential to create both highly potent therapeutic antibodies, as well as vaccines to immunize against the RECAF receptor. The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Some information included in this press release contains statements that are forward-looking. Such forward-looking information involves significant risks and uncertainties that could affect anticipated results in the future and, accordingly, these results may differ materially from those expressed in any forward-looking statements made by or on behalf of the Company. For a description of additional risks and uncertainties, please refer to the Company's filings with the Securities and Exchange Commission. On behalf of the Board of Directors, Mr. Edward Velton, President Contact: For RJV Network, Inc. Grant Young Company Name----------------RJV Networks, Inc. Symbol----------------------RJVN Current Price---------------$0.26 52 Week High----------------$2.10 52 Week Low-----------------$0.26 Target $4 -to- $6 Q1/2003 Investment Highlights RJVN projects it will be able to treat most cancers with its combined targeted therapy treatment which is based upon an astounding discovery by a molecular biologist at the Univ. of Michigan - The causal link to breast and most other malignancies and cancers in the protein Mammastatin. RJVN has developed a series of cancer treatment therapies which utilize pan-cancer market antibodies. Antibody therapies do not create chemical toxicity and, as such, are fast tracked through the regulatory approval process. Using this approach, RJVN is targeted to enter testing for its products in six months. RJVN's combination of two leading, well known technologies previously announced by BioCurex and InNexus Corp along with RJVN's key MAb protein replicating technology has allowed the Company to create a series of patented therapeutic products that many molecular biologists believe will treat most cancers. RJVN's R&D and Management are led by Dr. John Todd, Dr. Charles Morgan (a world renowned molecular biologist and 5 other industry leading Dr's all with several years experience in bio-tech development. ******************* Special Offer ******************* If you would like to be included in our mailing list, you will receive a 10 day free trial to a web site with real-time Level II quotes, research reports from major providers, analyst upgrades/downgrade info, Bulletin Board Promotion/Syndication Calendar (1st of its kind), and access to our trading chat rooms and to several message boards with real live professionals. Just click on this link: mailTo:[EMAIL PROTECTED]?Subject=Opt-in to send us an email, and you will be immediately added. Please be sure "opt-in" is in the subject line of the email. Thank you. ******Disclaimer Information within this email contains "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact and may be "forward looking statements." Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through the use of words such as "projects", "foresee", "expects", "will," "anticipates," "estimates," "believes," "understands" or that by statements indicating certain actions "may," "could," or "might" occur. All information provided within this email pertaining to investing, stocks, securities must be understood as information provided and not investment advice. Emerging Equity Alert advises all readers and subscribers to seek advice from a registered professional securities representative before deciding to trade in stocks featured within this email. None of the material within this report shall be construed as any kind of investment advice. In compliance with the Securities Act of 1933, Section17(b), Emerging Stock Alert discloses the receipt of 125,000 unrestricted shares of RJVN from a third party for the publication of this report. Be aware of an inherent conflict of interest resulting from such compensation due to our intent to profit from the liquidation of these shares. Shares may be sold at any time, even after positive statements have been made regarding the above company. All factual information in this report was gathered from public sources, including but not limited to SEC filings, Company Press Releases, and Market Guide. Emerging Equity Alert believes this information to be reliable but can make no guarantee as to its accuracy or completeness. Use of the material within this email constitutes your acceptance of these terms. ****** Advertising Disclaimer ****** We have received monetary payment for this mailing service. We hold no stocks and hold no personal interest in this company. ****** Remove instructions: This message has been sent to you in compliance with our strict anti-abuse regulations. We will continue to bring you valuable offers on the products and services that interest you most. If you do not wish to receive further mailings, please click below. You will not receive another email from us again. We respect all removal requests. To be immediately removed from our mailing lists just click on this link: MailTo:[EMAIL PROTECTED] . This message is an advertisement. Copyright 2000, 2001, 2002 all rights reserved.
